Delving into the Latest Updates on gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV) with Synapse

Overview

Basic Info

Drug Type

Vaccine

Synonyms

Trimeric Glycoprotein140(Crucell Holland BV)

Target-

Mechanism

Immunostimulants

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Crucell Holland B.V.

Active Organization-

Inactive Organization

Crucell Holland B.V.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to assess the safety and tolerability of 2 different dose levels of trimeric glycoprotein140 (gp140) administered as a 2-dosage regimen, intramuscularly (injection of a substance into a muscle), with and without aluminum phosphate as adjuvant in healthy human immunodeficiency virus (HIV)-uninfected participants.

Start Date01 Dec 2014

Sponsor / Collaborator

Crucell Holland B.V.

[+2]

100 Clinical Results associated with gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV)

Login to view more data

100 Translational Medicine associated with gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV)

Login to view more data

100 Patents (Medical) associated with gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV)

Login to view more data

100 Deals associated with gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV)

Login to view more data